These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24795013)

  • 21. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
    Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
    N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
    Dowdy SC; Stefanek M; Hartmann LC
    Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetics: predisposition and management.
    Legare RD
    Clin Obstet Gynecol; 2011 Mar; 54(1):180-90. PubMed ID: 21278518
    [No Abstract]   [Full Text] [Related]  

  • 24. Comment on Elit et al.: prophylactic oophorectomy in Ontario.
    Zweemer RP; Jacobs IJ
    Fam Cancer; 2001; 1(3-4):187-8. PubMed ID: 14574177
    [No Abstract]   [Full Text] [Related]  

  • 25. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations.
    Roukos DH; Agnanti NJ; Paraskevaidis E; Kappas AM
    Ann Surg Oncol; 2002 Dec; 9(10):941-3. PubMed ID: 12464584
    [No Abstract]   [Full Text] [Related]  

  • 26. Improving surveillance and quality of life of BRCA mutation carriers.
    Loman N; Borg A
    J Clin Oncol; 2010 Aug; 28(22):e376-7. PubMed ID: 20458044
    [No Abstract]   [Full Text] [Related]  

  • 27. Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations.
    Ann Intern Med; 2006 Mar; 144(6):I40. PubMed ID: 16549849
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
    Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Familiarity and heredity of tumors in function of an early surgical therapeutic approach].
    Ricevuto E; Di Rocco ZC; Cianci G; Bisegna R; Casilli F; De Galitiis F; Cannita K; Calista F; Porzio G; Bafile A; Vicentini R; Resta V; De Rubeis G; Martinotti S; Ficorella C; Marchetti P
    Suppl Tumori; 2002; 1(3):S89-91. PubMed ID: 12415797
    [No Abstract]   [Full Text] [Related]  

  • 31. Choice of management of southern Chinese BRCA mutation carriers.
    Kwong A; Wong CH; Shea C; Suen DT; Choi CL
    World J Surg; 2010 Jul; 34(7):1416-26. PubMed ID: 20182723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preconception counseling for the couple at risk preventing the hereditary breast and ovarian cancer syndrome.
    Beller U
    Int J Gynecol Cancer; 2010 Oct; 20(11 Suppl 2):S29-30. PubMed ID: 20975358
    [No Abstract]   [Full Text] [Related]  

  • 33. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
    Biglia N; Mariani L; Ponzone R; Sismondi P
    Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
    [No Abstract]   [Full Text] [Related]  

  • 34. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
    Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
    Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
    Haldar K; Crawford R
    Maturitas; 2010 Nov; 67(3):290. PubMed ID: 20869823
    [No Abstract]   [Full Text] [Related]  

  • 36. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.
    Haber D
    N Engl J Med; 2002 May; 346(21):1660-2. PubMed ID: 12024000
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oophorectomy in carriers of BRCA mutations.
    Anderson WF; Brawley OW; Chang S
    N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353512
    [No Abstract]   [Full Text] [Related]  

  • 39. Association of risk-reducing surgery with cancer risks and mortality in BRCA mutation carriers.
    Heemskerk-Gerritsen BA; Kriege M; Seynaeve C
    JAMA; 2010 Dec; 304(24):2695; author reply 2695-6. PubMed ID: 21177502
    [No Abstract]   [Full Text] [Related]  

  • 40. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.